Literature DB >> 17952090

TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Ekihiro Seki1, Samuele De Minicis, Christoph H Osterreicher, Johannes Kluwe, Yosuke Osawa, David A Brenner, Robert F Schwabe.   

Abstract

Hepatic injury is associated with a defective intestinal barrier and increased hepatic exposure to bacterial products. Here we report that the intestinal bacterial microflora and a functional Toll-like receptor 4 (TLR4), but not TLR2, are required for hepatic fibrogenesis. Using Tlr4-chimeric mice and in vivo lipopolysaccharide (LPS) challenge, we demonstrate that quiescent hepatic stellate cells (HSCs), the main precursors for myofibroblasts in the liver, are the predominant target through which TLR4 ligands promote fibrogenesis. In quiescent HSCs, TLR4 activation not only upregulates chemokine secretion and induces chemotaxis of Kupffer cells, but also downregulates the transforming growth factor (TGF)-beta pseudoreceptor Bambi to sensitize HSCs to TGF-beta-induced signals and allow for unrestricted activation by Kupffer cells. LPS-induced Bambi downregulation and sensitization to TGF-beta is mediated by a MyD88-NF-kappaB-dependent pathway. Accordingly, Myd88-deficient mice have decreased hepatic fibrosis. Thus, modulation of TGF-beta signaling by a TLR4-MyD88-NF-kappaB axis provides a novel link between proinflammatory and profibrogenic signals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17952090     DOI: 10.1038/nm1663

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  781 in total

Review 1.  Hepatic stellate cells and innate immunity in alcoholic liver disease.

Authors:  Yang-Gun Suh; Won-Il Jeong
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells.

Authors:  Jan Petrasek; Angela Dolganiuc; Timea Csak; Bharath Nath; Istvan Hritz; Karen Kodys; Donna Catalano; Evelyn Kurt-Jones; Pranoti Mandrekar; Gyongyi Szabo
Journal:  Hepatology       Date:  2011-01-10       Impact factor: 17.425

Review 3.  Functional role of chemokines in liver disease models.

Authors:  Hacer Sahin; Christian Trautwein; Hermann E Wasmuth
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-26       Impact factor: 46.802

4.  Toll-like receptor deficiency worsens inflammation and lymphedema after lymphatic injury.

Authors:  Jamie C Zampell; Sonia Elhadad; Tomer Avraham; Evan Weitman; Seth Aschen; Alan Yan; Babak J Mehrara
Journal:  Am J Physiol Cell Physiol       Date:  2011-11-02       Impact factor: 4.249

Review 5.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

Review 6.  Hepatocyte death: a clear and present danger.

Authors:  Harmeet Malhi; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

7.  Sophocarpine attenuates liver fibrosis by inhibiting the TLR4 signaling pathway in rats.

Authors:  Hui Qian; Jian Shi; Ting-Ting Fan; Jiao Lv; Si-Wen Chen; Chun-Yan Song; Zhi-Wu Zheng; Wei-Fen Xie; Yue-Xiang Chen
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 8.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

9.  A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.

Authors:  David J Konieczkowski; Cory M Johannessen; Omar Abudayyeh; Jong Wook Kim; Zachary A Cooper; Adriano Piris; Dennie T Frederick; Michal Barzily-Rokni; Ravid Straussman; Rizwan Haq; David E Fisher; Jill P Mesirov; William C Hahn; Keith T Flaherty; Jennifer A Wargo; Pablo Tamayo; Levi A Garraway
Journal:  Cancer Discov       Date:  2014-04-25       Impact factor: 39.397

10.  Microbiome-Immune Interactions and Liver Disease.

Authors:  James H Tabibian; Cyril Varghese; Steven P O'Hara; Nicholas F LaRusso
Journal:  Clin Liver Dis (Hoboken)       Date:  2015-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.